Binod Dhakal, MD, associate professor, division of hematology and oncology, Medical College of Wisconsin and lead investigator of the CARTITUDE-4 study, presented updated data at the 2024 International Myeloma Society conference.
Binod Dhakal, MD, associate professor, division of hematology and oncology, Medical College of Wisconsin and lead investigator of the CARTITUDE-4 study, attended the 21st International Myeloma Society (IMS) Annual Meeting in Rio de Janeiro, Brazil, between September 25 to 28.
Dhakal discussed the methods utilized in the CARTITUDE-4 study and the outcomes it had on patients with relapsed or refractory multiple myeloma. The study compared ciltacabtagene autoleucel (cilta-cel) with standard of care in patients with refractory multiple myeloma.
This transcript has been lightly edited for clarity.
Transcript
What are the latest data on CARTITUDE-4 being presented at IMS this year?
As you know, CARTITUDE-4 is a phase 3 randomized study comparing cilta-cel vs standard of care in patients with 1 to 3 prior lines of therapy and were [lenalidomide] refractory. In the initial presentation of the primary analysis, we found that CARTITUDE-4 cilta-cel [ciltacabtagene autoleucel] has significant benefit in the progression-free survival compared to standard of care with a hazard ratio of 0.26.
That was about a 15.9 month follow up. At the IMS meeting, we are presenting a median follow up of 33.6 months. The previous specified analysis of overall survival was considered along with the updated overall survival, efficacy, and safety outcomes, with the cilta-cel or with the standard of care.
There were 419 patients randomized, 282 cilta-cel and 211 to standard of care, which is one of the either daratumumab, pomalidomide, and dexamethasone (DPd) or pomalidomide, bortezomib, and dexamethsaone (PVd).
At a median follow-up of 33.6 months, we saw that the median overall survival was not reached in either arm with cilta-cel or standard of care. Overall survival significantly improved [vs] standard of care, with the hazard ratio 0.55 and significant P value. The 30-month overall survival rates were 76% in the cilta-cell arm vs 64% in the standard-of-care arm.
Overall survival benefited all subgroups in the cilta-cel arm compared with standard of care. In terms of immediate progression-free survival, it was still not reached at that follow-up with cilta-cel [arm] vs 11.8 months in the standard of care, and the hazard ratio is 0.29.
In terms of safety that was consistent with previous interim analysis, there were deaths occurring among 50 patients in the cilta-cel arm and 82 patients in the standard of care arm with 21 patients and 51 respectively, who died of progressive disease.
This study is the first study in myeloma that [showed] a survival benefit with the BMCA CAR [chimeric antigen receptor] T, in this case using cilta-cel and significantly reduced the risk of death by about 45% of those patients who received a cilta-cel in as early as first relapse.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
ALL Disparities, Treatment Gaps: AYA Patients Face Unique Challenges
June 4th 2025Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and unmet needs for effective third-line treatments, highlighting urgent care gaps.
Read More
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More